To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

June 02, 2020___

Today's Rundown

Featured Story

Pfizer to funnel $500M into biotechs, offering 'crucial capital' during the COVID-19 crisis

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Top Stories

In conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center

From chief scientific officer of Bristol Myers Squibb (back when it still had a hyphen) to running one of the biggest cancer research organizations in the world is a major career shift and challenge at the best of times.

Stanford researcher Genovese joins Gilead to lead NASH, arthritis programs

Gilead Sciences is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its nonalcoholic steatohepatitis, fibrosis and arthritis pipeline programs.

Hahn: Permanently adopting R&D-accelerating COVID-19 measures is a top FDA priority

FDA Commissioner Stephen Hahn, M.D., has vowed to permanently adopt COVID-19-driven changes that make reviews and authorizations faster. Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development. 

I-MAB advances repositioned RA drug in early trial to treat COVID-19 cytokine storm

China-based I-MAB Biopharma is advancing its GM-CSF inhibitor into the second phase of a trial in COVID-19 cytokine release syndrome. The company's scientists believe that because the drug works "upstream" in the pro-inflammatory pathway, it will inhibit several cytokines that cause the dangerous syndrome.

Abiomed gets Impella pump EUA for coronavirus-related heart failure

The FDA granted an emergency authorization to Abiomed’s Impella RP heart pump system for COVID-19 patients suffering from right-sided heart failure, including those with a pulmonary embolism.

Hillhouse leads $160M round for Chinese antibody maker Genor

China’s Genor Biopharma banked $160 million from the likes of Hillhouse Capital and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs, prepare the launch of its most advanced prospects and support early-stage R&D. The funds will also support potential partnerships at home and abroad.

Enrollment Showcase

A Credential for the Future of Health Care

Position yourself as a precision medicine leader with the online graduate program in precision medicine. Learn the latest in genomic technologies and precision medicine therapies from experts in research and implementation. Join the future of health care with the flexibility and convenience of an online program.

Resources

[Whitepaper] 7 Keys to Success in Europe

White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe.

[Whitepaper] Rapid BYOD Build Timelines

This white paper covers a Phase III case study; BYOD advantages and misconceptions; and regulatory, copyright, and equivalency considerations.

[Whitepaper] Keep Your GI Trials Moving During COVID-19

Learn how GI specific data capture solutions can support virtual and hybrid trials during COVID-19.

[Whitepaper] The Evolution and Importance of Biomedical Ontologies for Scientific Literature

Dive into the history of biomedical classification and how these systems have evolved to address new technology and use cases.

[Case Study] Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

[Fact Sheet] Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

[eBook] Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

[Podcast] Developing residual HCPs ELISA assay for biopharmaceutical products

Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits.

[Virtual Event] Cardiac Safety London Online

Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research.

[Report] Decentralized Trials - Where Does the Industry Stand?

Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual."

[Whitepaper] Covid-19 Requires a Cloud Strategy to Succeed in the “New Normal”

Covid-19 has forever changed the paradigm of “go to the office” business operations. Learn how an effective Cloud Strategy can position your company for success in these unprecedented times.

[Whitepaper] Flexible Design for Novel Trials

Download this case study to read about how Cenduit navigated these challenges, and successfully supports the trial sponsor to execute the umbrella trial with agility.

[Case Study] More Powerful Analytics Capabilities

Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI.

[Case Study] Precision Analytics for Product Launch and Growth

Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. 

Events